KBC Group NV Purchases 600 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

KBC Group NV lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 89.2% during the 4th quarter, HoldingsChannel reports. The firm owned 1,273 shares of the specialty pharmaceutical company’s stock after acquiring an additional 600 shares during the period. KBC Group NV’s holdings in ANI Pharmaceuticals were worth $70,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans lifted its position in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of ANI Pharmaceuticals by 3.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock worth $477,000 after acquiring an additional 300 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after acquiring an additional 310 shares during the period. New York State Teachers Retirement System boosted its stake in ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after acquiring an additional 394 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in ANI Pharmaceuticals by 5.2% in the third quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock worth $564,000 after purchasing an additional 464 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ANIP shares. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Truist Financial increased their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $77.71.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock worth $2,441,556 in the last three months. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $59.59 on Tuesday. The firm has a fifty day simple moving average of $56.74 and a two-hundred day simple moving average of $58.40. The firm has a market cap of $1.25 billion, a PE ratio of -108.35 and a beta of 0.74. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.05 earnings per share. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.